High Tower Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

High Tower Advisors, LLC

  • $64.2 Billion
  • Q2 2024

A detailed history of High Tower Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, High Tower Advisors, LLC holds 53,094 shares of VRTX stock, worth $27.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
53,094
Previous 57,286 7.32%
Holding current value
$27.4 Million
Previous $23.9 Million 3.93%
% of portfolio
0.04%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$392.81 - $485.53 $1.65 Million - $2.04 Million
-4,192 Reduced 7.32%
53,094 $24.9 Million
Q1 2024

May 06, 2024
SELL
$407.69 - $446.08 $10.3 Million - $11.2 Million
-25,163 Reduced 30.52%
57,286 $23.9 Million
Q4 2023

Feb 12, 2024
SELL
$343.0 - $410.68 $2.07 Million - $2.48 Million
-6,045 Reduced 6.83%
82,449 $33.5 Million
Q3 2023

Nov 08, 2023
BUY
$338.18 - $362.46 $1.54 Million - $1.65 Million
4,553 Added 5.42%
88,494 $30.8 Million
Q2 2023

Aug 14, 2023
BUY
$314.42 - $351.91 $7.21 Million - $8.07 Million
22,918 Added 37.56%
83,941 $29.5 Million
Q1 2023

May 11, 2023
SELL
$283.23 - $323.1 $794,460 - $906,295
-2,805 Reduced 4.39%
61,023 $19.2 Million
Q4 2022

Feb 08, 2023
BUY
$285.76 - $321.48 $3.96 Million - $4.46 Million
13,869 Added 27.76%
63,828 $18.4 Million
Q3 2022

Nov 09, 2022
SELL
$273.83 - $305.53 $2.15 Million - $2.4 Million
-7,848 Reduced 13.58%
49,959 $14.5 Million
Q2 2022

Aug 10, 2022
SELL
$234.96 - $292.55 $8.58 Million - $10.7 Million
-36,502 Reduced 38.7%
57,807 $16.3 Million
Q1 2022

May 12, 2022
BUY
$221.42 - $260.97 $6.52 Million - $7.68 Million
29,446 Added 45.4%
94,309 $24.6 Million
Q4 2021

Feb 10, 2022
BUY
$177.01 - $223.45 $1.98 Million - $2.5 Million
11,205 Added 20.88%
64,863 $14.2 Million
Q3 2021

Nov 12, 2021
BUY
$181.39 - $202.99 $7.31 Million - $8.18 Million
40,274 Added 300.91%
53,658 $9.69 Million
Q2 2021

Aug 06, 2021
SELL
$187.49 - $221.1 $422,039 - $497,696
-2,251 Reduced 14.4%
13,384 $2.69 Million
Q1 2021

May 10, 2021
BUY
$207.02 - $241.31 $3.24 Million - $3.77 Million
15,635 New
15,635 $3.36 Million
Q4 2020

Feb 10, 2021
SELL
$207.01 - $276.09 $2.73 Million - $3.64 Million
-13,185 Closed
0 $0
Q3 2020

Nov 13, 2020
BUY
$255.65 - $303.1 $461,703 - $547,398
1,806 Added 15.87%
13,185 $3.59 Million
Q2 2020

Aug 10, 2020
BUY
$225.48 - $295.8 $317,926 - $417,078
1,410 Added 14.14%
11,379 $3.31 Million
Q1 2020

May 21, 2020
SELL
$199.77 - $247.81 $38,555 - $47,827
-193 Reduced 1.9%
9,969 $2.38 Million
Q4 2019

Feb 14, 2020
BUY
$166.71 - $223.91 $250,398 - $336,312
1,502 Added 17.34%
10,162 $2.23 Million
Q3 2019

Nov 12, 2019
BUY
$166.23 - $187.09 $325,478 - $366,322
1,958 Added 29.22%
8,660 $1.47 Million
Q2 2019

Aug 13, 2019
BUY
$164.61 - $190.37 $192,593 - $222,732
1,170 Added 21.15%
6,702 $1.23 Million
Q1 2019

May 15, 2019
SELL
$163.73 - $194.7 $223,655 - $265,960
-1,366 Reduced 19.8%
5,532 $1.02 Million
Q4 2018

Feb 14, 2019
SELL
$151.91 - $192.21 $513,911 - $650,246
-3,383 Reduced 32.91%
6,898 $1.14 Million
Q3 2018

Nov 09, 2018
BUY
$167.73 - $192.74 $553,005 - $635,463
3,297 Added 47.21%
10,281 $1.99 Million
Q2 2018

Aug 14, 2018
BUY
$145.72 - $169.96 $39,927 - $46,569
274 Added 4.08%
6,984 $1.19 Million
Q1 2018

May 15, 2018
SELL
$151.6 - $177.13 $204,053 - $238,416
-1,346 Reduced 16.71%
6,710 $1.09 Million
Q4 2017

Feb 14, 2018
SELL
$137.28 - $155.55 $1.09 Million - $1.23 Million
-7,931 Reduced 49.61%
8,056 $1.2 Million
Q3 2017

Nov 14, 2017
SELL
$148.13 - $162.24 $442,612 - $484,773
-2,988 Reduced 15.75%
15,987 $2.43 Million
Q2 2017

Aug 14, 2017
BUY
N/A
18,975
18,975 $2.45 Million

Others Institutions Holding VRTX

# of Institutions
1,717
Shares Held
226M
Call Options Held
1.19M
Put Options Held
1.56M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email